Purpose: To evaluate the efficacy and safety of 0.5% Timolol eye drop monotherapy as a first-line treatment for capillary hemangioma. Methods: Retrospective, consecutive, clinical case series Results: Medical records, including consequent photographs of children with capillary hemangioma treated consecutively with 0.5% timolol solution from October 1 st , 2017 to July 31 st , 2018 were reviewed.11 cases of capillary hemangioma, age 0-8 months, were treated with 0.5% Timolol eye drops applied to the lesions twice a day as monotherapy for at least one month. General physical examination, included vital signs, respiratory rate, skin lesions, and eye examination before treatment were performed at every follow-up visit.Eight of 11 cases showed improvement in size, thickness, and coloration of the lesions without any complications. All 8 cases showed clinical improvement within 2 months of treatment. One case had relapsed after treatment cessation and got better after re-treatment. One case was lost to follow up. One case failed the monotherapy and needed additive treatment with propranolol and vinblastine. Conclusion: 0.5% Timolol eye drop monotherapy can be used safely as a first-line treatment for capillary hemangioma, especially uncomplicated cases. Conflicts of interest:The authors report no confilcts of interest.

No abstract